Retrospective Viewpoint: Biotechnology Companies Keep Going with Mergers
In face of patent expiration or other threats, big pharmaceutics are facing challenges too. In priority, innovative technology or novel developments are necessary.
On 2010, Celgene declared the acquisition of ABII for $2.9 billion for cancer treatment.
On May 2011, Shire declared the acquisition of Advanced BioHealing for $750 million for Regenerative Medicine.
On Nov. 2011, Gilead Sciences Inc. declared the acquisition of Pharmasset Inc. for $11 billion for Hepatitis C.
On Jan. 2012, Amgen Inc. declared the acquisition of Micromet Inc. for $ 1.16 billion for anti-cancer.
On early 2012, Celgene declared the acquisition of Avila for $925 million for Hematologic cancers.
On Apr. 2012, Shire declared the acquisition of Pervasis for endothelial cell technology.
Meanwhile, top biotechnology companies are planning to purchase promising and even medium-sized companies. Then how about small biotech companies? Many companies, such as Advanced Life Sciences, Altair Therapeutics, Ambrilia Biopharma, ARYx Therapeutics, Peptimmune, Phenomix Corporation, Tolerx and Transdel have failed and had to shut down.
But with the main trend of biotech needs and world advancement, this field will keep going for a very long time and a very long road. Our company, Creative BioMart, will continuously develop with our core competencies and resources. Our recombinant proteins, for example, have gained outstanding achievements in the world.